Abstract
Objectives
This article focuses on the differences between CT findings of HIV-negative patients who have cavities with nontuberculous mycobacteria (NTM) disease and those with Mycobacterium tuberculosis infections (TB).
Methods
We retrospectively reviewed 128 NTM disease patients (79 males and 49 females) with cavities in chest CT, matched for age and gender with 128 TB patients in the same period. Sputum cultures of all patients were positive for pathogens. Two independent chest radiologists evaluated the characteristics of the largest cavity and related factors.
Results
Interobserver agreement was excellent (κ value, 0.853–0.938). Cavity walls in NTM disease were significantly thinner (6.9±4 mm vs 10.9±6 mm, P<0.001) and more even (the ratio of thickness, 2.6±1 vs 3.7±2, P<0.001) than those in TB. The thickening of adjacent pleura next to the cavity was also significantly thicker in NTM than TB (P<0.001). However, in the multivariate analysis, thickening of adjacent pleura was the only significant factor among the representative cavity findings (Odds ratio [OR], 6.49; P<0.001). In addition, ill-defined tree-in-bud nodules (OR, 8.82; P<0.001), number of non-cavitary nodules (≥10mm) (OR, 0.72; P = 0.003), and bronchiectasis in the RUL (OR, 5.3; P = 0.002) were significantly associated ancillary findings with NTM disease in the multivariate analysis.
Conclusions
The major cavities in NTM disease generally have thinner and more even walls than those in TB. When cavities are associated with adjacent pleural thickening, ill-defined satellite tree-in-bud nodules, or fewer non-cavitary nodules ≥10 mm, these CT findings are highly suggestive of NTM disease rather than TB.
Introduction
Nontuberculous mycobacteria (NTM) are ubiquitous in the environment and are increasingly being recognized as significant in chronic pulmonary infections [1]. The most frequently encountered NTM lung disease worldwide is caused by Mycobacterium avium-intracellulare complex (MAC) [2–4]. Although the incidence and prevalence of NTM disease vary between populations, both have tended to increase over time [4–9]. In South Korea as well, the isolation of NTM on both solid and liquid media, and NTM disease, have been increasing in clinical practice [10,11].
South Korea has an intermediate tuberculosis burden, and therefore it is important to distinguish NTM disease from Mycobacterium tuberculosis disease (TB). The evaluation of mycobacterial infections by sputum study, culture, and TB-PCR usually takes a long time, and a quicker way of discriminating the two diseases is necessary for prompt treatment. There are some differences in the conventional radiographic features between pulmonary NTM disease and TB. NTM disease tends to cause thin-walled cavities with less surrounding parenchymal infiltrate, to have less bronchogenic but more contiguous spread of disease, and produce more marked involvement of the pleura over the involved areas of the lungs on chest radiographs [1,12]. Thin section chest CT has shown that up to 90% of MAC patients with non-cavitary disease in the mid and lower lung fields have associated multifocal bronchiectasis, with many patients having clusters of small (<5 mm) nodules in the associated areas of lung [13–15]. However, cavities are common in both NTM disease [16] and TB [17] and are a hallmark of the active infectious state in both diseases [17,18].
To our knowledge, there are no previous studies that aimed to discriminate between the two diseases on the basis of CT of their representative cavities and associated ancillary findings. The CT characteristics of the cavities and associated ancillary findings might help clinicians and radiologists discriminate between the two disease entities and give prompt treatment to some patients. Therefore, the primary purpose of this study was to describe the differences between the CT findings of HIV-negative patients who have cavities with nontuberculous mycobacteria (NTM) disease and those with Mycobacterium tuberculosis infections (TB).
Materials and methods
Study population
This study was approved by the Institutional Review Board of our hospital (Approval number: 2016–0056), and the requirement for the patient informed consent was waived due to its retrospective manner.
The electronic database and the registry of mycobacterial infections (of T.S.S) of this academic tertiary referral institution were searched to identify NTM disease and TB patients proven by culture between November 2004 and December 2013. Finally, 177 NTM disease patients and 302 TB patients were identified. The former were diagnosed with NTM pulmonary infection and fulfilled the American Thoracic Society/Infectious Diseases Society of America criteria for the diagnosis of NTM disease [1].
The inclusion criteria for patients were as follows: a) at least one visible cavity lesion in CT (>10mm); b) TB or NTM proven by culture; c) CT images available before treatment; and d) >18-years-old. Subsequent exclusion criteria were as follows: a) poor image quality for evaluating lung lesions including cavities (n = 23); b) insufficient computerized medical records (n = 6); c) HIV-positive (n = 2); d) co-infection with other pathogens including invasive mold disease or pseudomonas (n = 16).
As a result, 128 NTM disease patients (79 males and 49 females) were finally identified. They were matched for age and gender with 128 TB patients in the same period. Fig 1 summarizes the patient selection process.
CT imaging protocol
Various CT units were used over the >10-year follow-up period: a Sensation 16, SOMATOM Definition, SOMATOM Definition flash, SOMATOM Definition AS+ scanner (all manufactured by Siemens Medical Systems, Erlangen, Germany), LightSpeed 16, LightSpeed Plus, or LightSpeed VCT scanner (manufactured by GE Healthcare, Milwaukee, WI). The scanning parameters were as follows: beam collimation, 16 x 0.75 mm, 32 x 0.6 mm, or 64 x 0.6 mm; beam pitch, 0.984:1; gantry rotation time, 0.5 seconds; field of view to fit; 120 kVp. An automated dose reduction system was used (CARE Dose 4D, Siemens Medical Solutions; Auto mA/ Smart mA, GE Healthcare) with the maximum allowable tube current set at 100–400 mAs. Three- or five-mm-thick images at 3-mm/5-mm intervals without gaps were reconstructed in the axial planes. Coronal reformations have been routinely performed at a slice thickness of 5 mm for all CT scans since 2008. For contrast enhancement, intravenous contrast medium (100 cc of 300 mgI/mL nonionic contrast) was administered at a rate of 2–3 mL/seconds using an automatic power injector.
CT interpretation
The CT scan nearest to the time of treatment, but before treatment, was selected for the radiologic review. The mean time between the first NTM and TB isolation and CT examination was 18.5±7.8 days (range, 0–34 days). These CT scans were retrospectively reviewed by 2 independent expert chest radiologists with 19 (M.Y.K) and 5 years (S.Y.O) of experience, respectively, blinded to the patient information, and patients were assigned in random order.
We evaluated the largest cavity in any of the six lobes of the lung (right upper lobe [RUL], right middle lobe [RML], right lower lobe [RLL], left upper lobe [LUL], lingular division, and left lower lobe [LLL]) as the main target lesion. The size of the cavity, the thickness of the cavity wall including the thinnest and thickest portions, the ratio of the thickest portion to the thinnest portion, and the prevalence of focal thickening of the pleura adjacent to the target cavity were evaluated in the lung window setting.
As ancillary findings we evaluated the size (mm, none, <3mm, 3-6mm, >6mm) and margins (ill-defined/well-defined) of the satellite branching centrilobular nodules (tree-in-bud pattern) surrounding the cavity, the presence of pleural effusion, number of non-cavitary nodules ≥10mm, the presence of bronchiectasis in any of the six lobes, and the presence of bronchiectasis involving more than 5 lobes.
Review of other clinical data
One of the authors (S.H.P with clinical experience of three years) reviewed the medical charts. Age, gender, body mass index (BMI), smoking history, previous TB history, underlying disease (DM, the status of diabetes control, malignancy, and chronic obstructive pulmonary disease [COPD]), initial symptoms (cough, sputum, hemoptysis, dyspnea, or fever), and laboratory findings (albumin, white blood cell [WBC], C-reactive protein [CRP]) of all the study patients were recorded. Uncontrolled DM was defined as glycated hemoglobin (HbA1C) level ≤ 7.0% [19]. NTM pathogens proven in culture were also recorded.
Statistical analysis
To compare clinical, demographic, and CT findings in the two study populations, Student’s t-test was used for continuous variables and the chi-square test for categorical variables. Variables were subjected to multivariate analysis by logistic regression and forward stepwise selection after univariate analysis. Interobserver variation was quantified by κ coefficients of agreement (κ values of 0.00–0.20, poor agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, good agreement; and 0.81–1.00, excellent agreement). A P value < 0.05 was considered significant. All statistical analyses were performed with SPSS package, version 21.0 (SPSS, Chicago, Ill) by an expert statistician (S.S.K., 10 years’ experience).
Results
Comparison of the clinical characteristics of the two study populations
Clinical findings for the two study population are summarized in Table 1. The BMI of the NTM disease patients was lower than that of the TB patients (P<0.001). There were no significant differences in age and gender. Never smokers and patients with previous histories of TB were more common in the NTM disease group (P<0.001). DM and COPD were more common in TB (P<0.001 and P = 0.045, respectively). Among DM patients, the status of diabetes control was not significantly different between NTM and TB patients. The significant factors in multivariate analysis were never smoker (OR [odds ratio], 6.52; CI [confidence interval], 1.88–22.6; P = 0.003), previous TB history (OR, 3.57; CI, 1.23–10.4; P = 0.02), and dyspnea (OR, 0.05; CI, 0.003–0.73; P = 0.03). M. intracellulare was the most common pathogen in the NTM disease group (48.4%), followed by M. avium (30%), M. abscessus (11.7%), M. kansasii (6.3%), and others (3.9%) including M. chimaera, M. szulgai, M. chelonae, and M. fortuitum. The proportion of patients with a positive sputum AFB smear was similar between NTM and TB group (49.2% [63/128] vs. 46.1% [59/128], P = 0.532).
Table 1. Clinical characteristics of 256 patients with nontuberculous mycobacterial infections and Mycobacterium tuberculosis infections.
Clinical findinga | NTM (%) (n = 128) | TB (%) (n = 128) | P-value | |
---|---|---|---|---|
Age (years, mean±SD)b | 60.8±13.1 | 60.2±10.4 | 0.666 | |
Gender | >0.999 | |||
Male | 79 (61.7) | 79 (61.7) | ||
Female | 49 (38.3) | 49 (38.3) | ||
BMIb | 20.3±3.0 | 22.1±2.9 | <0.001 | |
Smoking | <0.001 | |||
Current smoker | 14 (10.9) | 49 (38.3) | ||
Ex-smoker | 44 (34.4) | 39 (30.5) | ||
Never smoker | 70 (54.7) | 40 (31.3) | ||
Previous PTB history | 62 (48.4) | 17 (13.3) | <0.001 | |
Underlying disease | ||||
DM | 14 (10.9) | 46 (35.9) | <0.001 | |
Status of diabetes control | 0.535* | |||
• Well-controlled DM | 7 (50) | 63) | ||
• Uncontrolled DM | 7 (50) | 17 (37) | ||
Malignancy | 9 (7.0) | 17 (13.3) | 0.098 | |
Chronic lung disease | ||||
COPD | 12 (9.4) | 23 (18) | <0.045 | |
ILD | 11 (8.6) | 5 (3.9) | 0.121 | |
Symptom | ||||
Cough | 107 (83.6) | 82(64.1) | <0.001 | |
Sputum | 91 (71.1) | 69(53.9) | 0.005 | |
Hemoptysis | 35 (27.3) | 16(12.5) | 0.003 | |
Dyspnea | 1 (0.8) | 19(14.8) | <0.001 | |
Fever | 9 (7.0) | 5(3.9) | 0.272 | |
Laboratory findingb | ||||
Albumin (g/dL, mean±SD) | 3.7±0.6 | 3.5±0.6 | 0.091 | |
White blood cell (uL, mean±SD) | 6880±2068 | 7365±2209 | 0.074 | |
C-reactive protein (mg/dL, mean±SD) | 1.6±2.0 | 2.4±3.3 | 0.051 |
NTM = Nontuberculous mycobacteria, TB = Mycobacterium tuberculosis infection, SD = standard deviation, BMI = body mass index, COPD = chronic obstructive pulmonary disease, ILD = interstitial lung disease.
*Significance within DM patients, not in the whole study population
a chi-square test
b Student’s t-test
Comparison of the CT findings in the study populations
Interobserver agreement between the two readers was excellent (κ value, 0.853–0.938). The CT findings are presented in Table 2. In the analysis of the largest cavities, both the thickest and the thinnest cavity walls were thinner in NTM disease than in TB (6.9±3.7mm vs. 10.9±5.6mm, P<0.001; 2.8±1.2mm vs. 3.4±1.8mm, P = 0.003) (Figs 2 and 3). The ratio of the thickest to the thinnest portion, representing the irregularity of the cavity lesion, was lower in NTM disease than TB (2.6±1.4 vs. 3.7±2.1, P<0.001), and thickening of the pleura next to target cavity was more common in NTM disease (80/128 patients [62.5%] vs. 32/128 [25%], P<0.001) (Fig 4). In the sub-analysis of the cavity characteristics in which we excluded patients with uncontrolled DM, the results were the same as the results from the whole patient population (See S1 Table).
Table 2. CT findings of 256 patients with nontuberculous mycobacterial pulmonary infections and Mycobacterial tuberculosis infections.
CT findinga | NTM (%) (n = 128) | TB (%) (n = 128) | P-value | |
---|---|---|---|---|
Representative cavity | ||||
Size (mm)b | 33±16 | 41±61 | 0.163 | |
Location (%) | 0.178 | |||
RUL | 52 (41) | 52 (41) | ||
RML | 6 (4.7) | 1 (0.8) | ||
RLL | 27 (21) | 22 (17) | ||
LUL | 28 (22) | 32 (25) | ||
Lingular division | 4 (3) | 0 (0) | ||
LLL | 11 (9) | 21 (16) | ||
Both upper lobes | 80 (63) | 84 (66) | 0.602 | |
Thickness of the thickest cavity wall (mm, mean±SD)b | 6.9±4 | 10.9±6 | <0.001 | |
Thickness of the thinnest cavity wall (mm, mean±SD)b | 2.8±1 | 3.4±2 | 0.003 | |
The ratio of thicknessb | 2.6±1 | 3.7±2 | <0.001 | |
Thickening of adjacent pleura (%) | 80 (63) | 32 (25) | <0.001 | |
Ancillary finding | ||||
Satellite tree-in-bud pattern nodules, size (%) | <0.001 | |||
None | 1 (0.8) | 5 (4) | ||
<3 mm | 79 (62) | 15 (12) | ||
3–6 mm | 31 (24) | 50 (39) | ||
>6mm | 17 (13) | 58 (45) | ||
Satellite tree-in-bud pattern nodules, margin (%) | <0.001 | |||
Ill-defined | 92 (72) | 21 (17) | ||
Well-defined | 36 (28) | 103 (83) | ||
Pleural effusion (%) | 5 (4) | 4 (3) | 0.749 | |
Number of non-cavitary nodules (≥10mm)b | 1.0±2 | 1.7±2 | 0.007 | |
Bronchiectasis (%) | ||||
RUL | 65 (51) | 11 (9) | <0.001 | |
RML | 59 (46) | 10 (8) | <0.001 | |
RLL | 50 (39) | 10 (8) | <0.001 | |
LUL | 41 (32) | 10 (8) | <0.001 | |
Lingular division | 46 (36) | 9 (7) | <0.001 | |
LLL | 27 (21) | 10 (8) | 0.003 | |
Bronchiectasis involving > 5 lobes (%) | 19 (15) | 1 (0.8) | <0.001 |
NTM = Nontuberculous mycobacteria, TB = Mycobacterium tuberculosis infection, SD = standard deviation, RUL = right upper lobe, RML = right middle lobe, RLL = right lower lobe, LUL = left upper lobe, LLL = left lower lobe.
a chi-square test
b Student’s t-test
With respect to ancillary findings, satellite tree-in-bud pattern nodules surrounding cavities < 3 mm with ill-defined margins were more common in NTM disease than in TB (P<0.001) (Figs 5 and 6). At the same time there were fewer non-cavitary macro-nodules (≥10mm) in NTM disease than in TB (P = 0.007). Bronchiectasis in both lungs was more frequent in NTM disease than TB (all P<0.001 except for LLL [P = 0.003) as was bronchiectasis involvement of > 5 lobes (P<0.001).
In the univariate analysis, the thickness of the thickest cavity wall (OR, 0.96; CI, 0.94–0.99; P = 0.002), the ratio of thickness (OR, 0.92; CI, 0.86–0.99; P = 0.022), thickening of adjacent pleura (OR, 2.5; CI, 1.66–3.77; P<0.001), tree-in-bud pattern nodules <3 mm (OR, 4; CI, 2.45–6.53; P<0.001), ill-defined tree-in-bud nodules (OR, 4.38; CI, 2.73–7.04; P<0.001), number of non-cavitary nodules (≥10mm) (OR, 0.88; CI, 0.79–0.98; P = 0.025), bronchiectasis in all lobes (RUL: OR, 5.91; CI, 3.12–11.2; P<0.001, RML: OR, 5.9; CI, 3.02–11.5; P<0.001, RLL: OR, 5; CI, 2.54–9.86; P<0.001, LUL: OR, 4.1; CI, 2.05–8.19; P<0.001, lingular division: OR, 5.11; CI, 2.5–10.4; P<0.001, and LLL: OR, 2.7; CI, 1.31–5.58; P = 0.007), and the presence of bronchiectasis involving more than 5 lobes (OR, 19; CI, 2.54–141.9; P = 0.004) were associated with NTM disease.
Multivariate analysis logistic regression was calculated for the variables which were significantly associated with NTM disease in the univariate analysis. The thickening of adjacent pleura (OR, 5.54; CI, 2.02–15.2; P = 0.001), ill-defined tree-in-bud nodules (OR, 8; CI, 2.1–30.4; P = 0.002), number of non-cavitary nodules (≥10mm) (OR, 0.72; CI, 0.56–0.9; P = 0.015), and bronchiectasis in RUL (OR, 4.7; CI, 1.3–16.4; P = 0.015) were significantly associated with NTM disease. The results of univariate and multivariate analysis to identify CT findings and also clinical findings in predicting NTM disease are shown in Table 3.
Table 3. Results of univariate and multivariate analysis.
Univariate analysis | Multivariate analysis | ||||||
---|---|---|---|---|---|---|---|
Variable | OR | 95% CI | P value | OR | 95% CI | P value | |
Representative cavity | |||||||
Thickness of the thickest cavity wall (mm) | 0.96 | 0.94–0.99 | 0.002 | ||||
Thickness of the thinnest cavity wall (mm) | 0.95 | 0.89–1.02 | 0.190 | ||||
The ratio of thickness | 0.92 | 0.86–0.99 | 0.022 | ||||
Thickening of adjacent pleura | 2.5 | 1.65–3.78 | 0.001 | 5.54 | 2.02–15.2 | 0.001 | |
Ancillary finding | |||||||
Satellite tree-in-bud pattern nodules (referent to >6 mm) | |||||||
<3 mm | 4 | 2.45–6.53 | <0.001 | ||||
3–6 mm | 0.62 | 0.4–0.97 | 0.037 | ||||
Margin of tree-in-bud pattern nodules (referent to well-defined) | |||||||
Ill-defined | 4.38 | 2.73–7.04 | <0.001 | 8 | 2.1–30.4 | 0.002 | |
Number of non-cavitary nodules (≥10mm) | 0.88 | 0.79–0.98 | 0.025 | 0.72 | 0.56–0.9 | 0.015 | |
Bronchiectasis | |||||||
RUL | 5.91 | 3.12–11.2 | <0.001 | 4.7 | 1.3–16.4 | 0.015 | |
RML | 5.9 | 3.02–11.5 | <0.001 | ||||
RLL | 5 | 2.54–9.86 | <0.001 | ||||
LUL | 4.1 | 2.05–8.19 | <0.001 | ||||
Lingular division | 5.11 | 2.5–10.4 | <0.001 | ||||
LLL | 2.7 | 1.31–5.58 | 0.007 | ||||
Bronchiectasis involving > 5 lobes | 19 | 2.54–141.9 | 0.004 | ||||
Clinical finding | |||||||
BMI | 0.99 | 0.98–1 | 0.343 | ||||
Smoking (reference to current smoker) | |||||||
Ex-smoker | 1.13 | 0.73–1.74 | 0.583 | ||||
Never smoker | 1.75 | 1.19–2.58 | 0.005 | 6.52 | 1.88–22.6 | 0.003 | |
Previous TB history | 3.65 | 2.13–6.24 | <0.001 | 3.57 | 1.23–10.4 | 0.02 | |
Underlying disease | |||||||
DM | 0.3 | 0.17–0.55 | <0.001 | ||||
Symptom | |||||||
Cough | 1.3 | 0.98–1.74 | 0.07 | ||||
Sputum | 1.32 | 0.96–1.8 | 0.083 | ||||
Hemoptysis | 2.19 | 1.21–3.95 | 0.009 | ||||
Dyspnea | 0.05 | 0.01–0.39 | 0.004 | 0.05 | 0.003–0.74 | 0.03 |
OR = odds ratio, CI = confidence interval.
Discussion
We have reported CT findings in NTM disease and compared them with those in TB, focusing on the largest and most representative cavities and associated ancillary findings. Our results revealed the characteristics of the cavities in NTM disease, showing that they were thinner and more even walled than those seen in TB. However, in multivariate analysis, thickening of the pleura adjacent to cavities was the only significant factor of the representative cavity findings in the multivariate analysis.
There have been reports of some differences between TB and NTM in the course of cavity formation, which could explain the different characteristics of the cavities in NTM disease and TB in our study: The cavity in TB is known to be formed by the coalescence of several tiny centrilobular cavities as the disease progresses [20,21], and in the stage of active caseous air-space consolidation, the cavity wall is usually thick and has an indistinct outer margin [17]. And these reports support our study results of relatively thicker and irregular walls of TB. For NTM disease, the previous study suggested that NTM disease begins with bronchial wall thickening, followed by peribronchial thickening or nodules, and develops into inflamed cystic bronchiectasis that manifests as cavities [22]. Therefore, we believe this study’s results also support the results of our study, in which we observed thinner and more even cavity walls in NTM.
It is possible that the thickness and sharpness of the cavity walls are dependent on the stage of the disease; however, the proportion of patients with a positive sputum AFB smear was similar between NTM and TB in our study, which could be used as a marker of disease activity. Additionally, WBC counts and CRP level, which were used as inflammatory biomarkers for disease activity in TB or NTM in previous studies [23,24], were not significantly different between TB and NTM disease.
Pleural thickening adjacent to the cavity was the most significant predictor for NTM disease in our study, but only few previous studies had been reported this finding [12]. Christensen et al. reported that thickening of the pleura immediately adjacent to cavities occurred in both NTM and TB, but it was more common with NTM disease than TB (56% of M. intracellularis, 37% of M. kansasii, and 24% of TB) [12,25]. In addition, extensive pleural thickening > 2 cm was more commonly observed in NTM disease than TB (16% of M. intracellularis, 3% of M. kansasii, and none of TB). This finding was thought to be due to a more indolent and chronic course of NTM disease. However, because these studies were performed using only chest radiographs, it was not possible to discern how much of pleural thickening was truly pleural and represented parenchymal disease in the wall of adjacent cavity.
Previously, although there have been several studies describing the characteristics of the cavities in NTM disease using radiographs or CT, there were no clear-cut differentiating features. Some studies reported that NTM disease tended to cause smaller and thinner-walled cavities than TB [12,16,25,26], but at least one found no difference in cavity wall thickness [27]. Furthermore, Moore et al. reported the presence of relatively thick-walled cavities in CT images of NTM disease [14]. However, we believe these previous studies have significant limitations: because they were performed in the 1980’-1990’s some used only chest radiographs, and the quality of the radiographs and CT images in these early studies must have been poorer than ours.
Our analysis of the ancillary findings revealed that smaller satellite tree-in-bud pattern nodules (< 3 mm), satellite nodules with ill-defined margin, fewer non-cavitary nodules of ≥10 mm, bronchiectasis in all lobes, and the presence of bronchiectasis involving > 5 lobes were more frequent in NTM disease than TB. Also, ill-defined nodule margins and rare non-cavitary macronodules (≥ 10 mm) were significant factors predicting NTM disease. In TB, bronchogenic dissemination is the most common route of spreading [21,28], and manifests as multiple, 5- to 10-mm nodules with segmental or lobar distributions [28]. NTM disease and TB are similar in terms of bronchogenic spreading, but the former has a more chronic, indolent course than TB. Microscopically there was also sloughing of the epithelial lining and circumferential replacement of the bronchial wall architecture by granulomatous inflammation [29]. Such differences in the patterns of progression of the two types of infection might be responsible for the differences in CT findings.
Radiologists as well as pulmonologists are generally unable to distinguish between NTM disease and TB, particularly in patients with dominant cavities, because of the considerable overlap in the clinical features of the two diseases [30]. In our study, symptoms such as cough, sputum, and hemoptysis were significantly more frequent in NTM disease and dyspnea was significantly more frequent in TB. However, we believe that these symptoms would not help clinicians distinguish between NTM disease and TB, because they are quite nonspecific.
In our study, there were 60 patients with DM, and they were significantly more numerous among the TB patients than among those with NTM disease. In previous reports, the presence of cavities was associated with HbA1C level, and cavity formation was significantly more common in uncontrolled DM patients than in non-DM patients [19,31]. Also, whereas a previous study showed no significant difference in the formation of cavities between non-DM and well-controlled DM in TB patients [19], there has yet to be any corresponding reports on NTM. In our study, there was no significant difference in the status of diabetes control among DM patients in NTM and TB patients. Considering the unknown effects of DM on cavity characteristics, we excluded patients with uncontrolled DM in the sub-analysis, which yielded no differences in comparison to the results of the whole study population. Therefore, uncontrolled DM may affect cavity formation in TB or NTM disease, but it may not affect the characteristics of the cavities. We believe further study is needed on this subject in order to clearly define the relationship between DM and cavities.
Because we matched age and gender in the patient selection process, there were no significant difference in age and gender between the patients with NTM disease and TB in our study. However, in previous studies, NTM disease was more frequent in older patients and postmenopausal women than TB [32–36].
This study had some limitations. First, it was a retrospective study in a single center in a country with semi-endemic TB. Therefore, some clinical characteristics may have been under- or over-estimated. Second, it included different species of NTM, which might have influenced the characteristics of the lesions, e.g. it has been reported that 84% of infective foci of M. kansasii had cavities [12,25]. In our study, only 6.3% of patients who had M. kansasii, and the most common pathogen was M. intracellulare. Therefore, further studies are necessary to compare the imaging characteristics of TB and M. kansasii in a larger population. Third, there were several confounding factors in patient selection such as history of TB, COPD, and DM which could not be completely excluded all.
In conclusion, the major cavities in NTM disease generally have thinner and more even walls than those in TB. When cavities are associated with adjacent pleural thickening, ill-defined satellite tree-in-bud nodules, or fewer non-cavitary nodules ≥10 mm, these CT findings are highly suggestive of NTM disease rather than TB.
Supporting information
Abbreviations
- AUC
area under the curve
- BMI
body mass index
- COPD
chronic obstructive pulmonary disease
- HIV
human immunodeficiency virus
- LLL
left lower lobe
- LUL
left upper lobe
- MAC
Mycobacterium avium-intracellulare complex
- NTM
nontuberculous mycobacteria
- RLL
right lower lobe
- RML
right middle lobe
- ROC
receiver operating characteristic
- RUL
right upper lobe
- TB
mycobacterium tuberculosis infection
Data Availability
All relevant data are within the paper and its Supporting Information files.
Funding Statement
The authors received no specific funding for this work.
References
- 1.Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. 10.1164/rccm.200604-571ST [DOI] [PubMed] [Google Scholar]
- 2.Koh WJ, Kwon OJ, Lee KS. Nontuberculous mycobacterial pulmonary diseases in immunocompetent patients. Korean J Radiol. 2002;3(3):145–57. 10.3348/kjr.2002.3.3.145 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Taiwo B, Glassroth J. Nontuberculous mycobacterial lung diseases. Infect Dis Clin North Am. 2010;24(3):769–89. 10.1016/j.idc.2010.04.008 [DOI] [PubMed] [Google Scholar]
- 4.Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan(1). Emerg Infect Dis. 2016;22(6):1116–7. 10.3201/eid2206.151086 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax. 2007;62(8):661–6. 10.1136/thx.2006.070797 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009;64(6):502–6. 10.1136/thx.2008.110957 [DOI] [PubMed] [Google Scholar]
- 7.Hosker HS, Lam CW, Ng TK, Ma HK, Chan SL. The prevalence and clinical significance of pulmonary infection due to non-tuberculous mycobacteria in Hong Kong. Respir Med. 1995;89(1):3–8. [DOI] [PubMed] [Google Scholar]
- 8.Lai CC, Tan CK, Chou CH, Hsu HL, Liao CH, Huang YT, et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000–2008. Emerg Infect Dis. 2010;16(2):294–6. 10.3201/eid1602.090675 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Andrejak C, Thomsen VO, Johansen IS, Riis A, Benfield TL, Duhaut P, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010;181(5):514–21. 10.1164/rccm.200905-0778OC [DOI] [PubMed] [Google Scholar]
- 10.Jeon K, Koh WJ, Kwon OJ, Suh GY, Chung MP, Kim H, et al. Recovery rate of NTM from AFB smear-positive sputum specimens at a medical centre in South Korea. Int J Tuberc Lung Dis. 2005;9(9):1046–51. [PubMed] [Google Scholar]
- 11.Park YS, Lee CH, Lee SM, Yang SC, Yoo CG, Kim YW, et al. Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. Int J Tuberc Lung Dis. 2010;14(8):1069–71. [PubMed] [Google Scholar]
- 12.Christensen EE, Dietz GW, Ahn CH, Chapman JS, Murry RC, Anderson J, et al. Initial roentgenographic manifestations of pulmonary Mycobacterium tuberculosis, M kansasii, and M intracellularis infections. Chest. 1981;80(2):132–6. [DOI] [PubMed] [Google Scholar]
- 13.Hartman TE, Swensen SJ, Williams DE. Mycobacterium avium-intracellulare complex: evaluation with CT. Radiology. 1993;187(1):23–6. 10.1148/radiology.187.1.8451419 [DOI] [PubMed] [Google Scholar]
- 14.Moore EH. Atypical mycobacterial infection in the lung: CT appearance. Radiology. 1993;187(3):777–82. 10.1148/radiology.187.3.8497629 [DOI] [PubMed] [Google Scholar]
- 15.Patz EF Jr., Swensen SJ, Erasmus J. Pulmonary manifestations of nontuberculous Mycobacterium. Radiol Clin North Am. 1995;33(4):719–29. [PubMed] [Google Scholar]
- 16.Miller WT Jr. Spectrum of pulmonary nontuberculous mycobacterial infection. Radiology. 1994;191(2):343–50. 10.1148/radiology.191.2.8153304 [DOI] [PubMed] [Google Scholar]
- 17.Goo JM, Im JG. CT of tuberculosis and nontuberculous mycobacterial infections. Radiol Clin North Am. 2002;40(1):73–87, viii [DOI] [PubMed] [Google Scholar]
- 18.Marras TK, Wagnetz U, Jamieson FB, Patsios DA. Chest computed tomography predicts microbiological burden and symptoms in pulmonary Mycobacterium xenopi. Respirology. 2013;18(1):92–101. 10.1111/j.1440-1843.2012.02277.x [DOI] [PubMed] [Google Scholar]
- 19.Yoon YS, Jung JW, Jeon EJ, Seo H, Ryu YJ, Yim JJ, et al. The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study. Thorax. 2016. [DOI] [PubMed] [Google Scholar]
- 20.Im JG, Itoh H, Lee KS, Han MC. CT-pathology correlation of pulmonary tuberculosis. Crit Rev Diagn Imaging. 1995;36(3):227–85. [PubMed] [Google Scholar]
- 21.Im JG, Itoh H, Shim YS, Lee JH, Ahn J, Han MC, et al. Pulmonary tuberculosis: CT findings—early active disease and sequential change with antituberculous therapy. Radiology. 1993;186(3):653–60. 10.1148/radiology.186.3.8430169 [DOI] [PubMed] [Google Scholar]
- 22.Kim TS, Koh WJ, Han J, Chung MJ, Lee JH, Lee KS, et al. Hypothesis on the evolution of cavitary lesions in nontuberculous mycobacterial pulmonary infection: thin-section CT and histopathologic correlation. AJR Am J Roentgenol. 2005;184(4):1247–52. 10.2214/ajr.184.4.01841247 [DOI] [PubMed] [Google Scholar]
- 23.Maekawa K, Ito Y, Oga T, Hirai T, Kubo T, Fujita K, et al. High-resolution computed tomography and health-related quality of life in Mycobacterium avium complex disease. Int J Tuberc Lung Dis. 2013;17(6):829–35. 10.5588/ijtld.12.0672 [DOI] [PubMed] [Google Scholar]
- 24.Singanayagam A, Manalan K, Connell DW, Chalmers JD, Sridhar S, Ritchie AI, et al. Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2016;20(12):1653–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Christensen EE, Dietz GW, Ahn CH, Chapman JS, Murry RC, Hurst GA. Radiographic manifestations of pulmonary Mycobacterium kansasii infections. AJR Am J Roentgenol. 1978;131(6):985–93. 10.2214/ajr.131.6.985 [DOI] [PubMed] [Google Scholar]
- 26.Albelda SM, Kern JA, Marinelli DL, Miller WT. Expanding spectrum of pulmonary disease caused by nontuberculous mycobacteria. Radiology. 1985;157(2):289–96. 10.1148/radiology.157.2.4048433 [DOI] [PubMed] [Google Scholar]
- 27.Lynch DA, Simone PM, Fox MA, Bucher BL, Heinig MJ. CT features of pulmonary Mycobacterium avium complex infection. J Comput Assist Tomogr. 1995;19(3):353–60. [DOI] [PubMed] [Google Scholar]
- 28.Im JG, Itoh H, Han MC. CT of pulmonary tuberculosis. Semin Ultrasound CT MR. 1995;16(5):420–34. [DOI] [PubMed] [Google Scholar]
- 29.O'Connell ML, Birkenkamp KE, Kleiner DE, Folio LR, Holland SM, Olivier KN. Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest. 2012;141(5):1203–9. 10.1378/chest.11-0425 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Kim YK, Hahn S, Uh Y, Im DJ, Lim YL, Choi HK, et al. Comparable characteristics of tuberculous and non-tuberculous mycobacterial cavitary lung diseases. Int J Tuberc Lung Dis. 2014;18(6):725–9. 10.5588/ijtld.13.0871 [DOI] [PubMed] [Google Scholar]
- 31.Chiang CY, Lee JJ, Chien ST, Enarson DA, Chang YC, Chen YT, et al. Glycemic control and radiographic manifestations of tuberculosis in diabetic patients. PLoS One. 2014;9(4):e93397 10.1371/journal.pone.0093397 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008;178(10):1066–74. 10.1164/rccm.200805-686OC [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Kendall BA, Varley CD, Choi D, Cassidy PM, Hedberg K, Ware MA, et al. Distinguishing tuberculosis from nontuberculous mycobacteria lung disease, Oregon, USA. Emerg Infect Dis. 2011;17(3):506–9. 10.3201/eid1703.101164 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Birring SS, Brightling CE, Bradding P, Entwisle JJ, Vara DD, Grigg J, et al. Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: a descriptive study. Am J Respir Crit Care Med. 2002;166(8):1078–83. [DOI] [PubMed] [Google Scholar]
- 35.Koh WJ, Yu CM, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Pulmonary TB and NTM lung disease: comparison of characteristics in patients with AFB smear-positive sputum. Int J Tuberc Lung Dis. 2006;10(9):1001–7. [PubMed] [Google Scholar]
- 36.Al Jarad N, Demertzis P, Jones DJ, Barnes NC, Rudd RM, Gaya H, et al. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis. Thorax. 1996;51(2):137–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All relevant data are within the paper and its Supporting Information files.